- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | First Faculty of Medicine
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | First Faculty of Medicine
- Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a2021 | First Faculty of Medicine
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer2017 | Faculty of Medicine in Hradec Králové
- Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study2015 | First Faculty of Medicine